Human papillomavirus-related genital disease in the immunocompromised host: Part II.

Rachel H Gormley, Carrie L Kovarik

Journal: Journal of the American Academy of Dermatology 2012;66(6):883.e1-17; quiz 899-900

PMID: 22583721

Full Text on Elsevier Science View on PubMed

Abstract

Human papillomavirus is responsible for common condyloma acuminata and a number of premalignant and malignant anogenital lesions. The immunocompromised population is at particular risk because of a higher incidence of malignant transformation. Lesions in this population may prove refractory to standard treatment. This is part II of a two-part review that will discuss the treatment of condyloma acuminata and vaginal, vulvar, penile, and anal intraepithelial neoplasias. This article will provide an updated review of available treatments, with a focus on recent advances and the challenges faced in successfully treating human papillomavirus lesions in the immunocompromised host.

Address: Department of Dermatology, Division of Infectious Diseases, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.

DOI: 10.1016/j.jaad.2010.12.049

Link outs

Free resources

Medical:

https://medlineplus.gov/vulvarcancer.html

Subscription / membership required

Full Text Sources:

MeSH Terms: Adjuvants, Immunologic, Alphapapillomavirus, Aminoquinolines, Antineoplastic Agents, Phytogenic, Antiviral Agents, Anus Neoplasms, Buschke-Lowenstein Tumor, Catechin, Caustics, Cidofovir, Condylomata Acuminata, Counseling, Cryotherapy, Cytosine, Female, Humans, Imiquimod, Immunocompromised Host, Male, Ointments, Organophosphonates, Papillomavirus Infections, Penile Neoplasms, Podophyllotoxin, Precancerous Conditions, Treatment Outcome, Trichloroacetic Acid, Vaginal Neoplasms, Vulvar Neoplasms, Warts